
Viridian Therapeutics, Inc. (NASDAQ:VRDN) reported upbeat results for the second quarter on Wednesday.
The company posted quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.02) per share. The company reported quarterly sales of $75.000 thousand which beat the analyst consensus estimate of $43.643 thousand.